In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment.
about
Methotrexate as combination partner of TNF inhibitors and tocilizumab. What is reasonable from an immunological viewpoint?Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitorsTherapeutic strategies for the clinical blockade of IL-6/gp130 signalingThe effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responsesSpotlight on tocilizumab and its potential in the treatment of systemic sclerosisPeripheral blood CD4(+)CD25(+)CD127(low) regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical response.Effects of a biologic agent in a patient with rheumatoid arthritis after treatment for methotrexate-associated B-cell lymphoma: a case report.CD27-IgD- memory B cells are modulated by in vivo interleukin-6 receptor (IL-6R) blockade in rheumatoid arthritis.Rational clinical trial design for antibody mediated renal allograft injury.Tocilizumab for the treatment of steroid refractory graft-versus-host disease.Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational studyDistinct Differentiation Programs Triggered by IL-6 and LPS in Teleost IgM(+) B Cells in The Absence of Germinal Centers.Immunotherapeutic implication of IL-6 blockade.To B or not to B the conductor of rheumatoid arthritis orchestra.Incompatible kidney transplantation: a brief overview of the past, present and future.Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases.Intravenous tocilizumab: a review of its use in adults with rheumatoid arthritis.Inhibition of the interleukin-6 signaling pathway: a strategy to induce immune tolerance.Atacicept as an investigated therapy for rheumatoid arthritis.Novel therapies for memory cells in autoimmune diseases.Molecular targets on B-cells to prevent and treat antibody-mediated rejection in organ transplantation. Present and Future.The role and therapeutic targeting of IL-6 in rheumatoid arthritis.Correction of abnormal B-cell subset distribution by interleukin-6 receptor blockade in polymyalgia rheumatica.Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis.A biallelic mutation in IL6ST encoding the GP130 co-receptor causes immunodeficiency and craniosynostosis.B-cell phenotype and IgD-CD27- memory B cells are affected by TNF-inhibitors and tocilizumab treatment in rheumatoid arthritis.Interleukin-6 receptor inhibition modulates the immune reaction and restores titin phosphorylation in experimental myocarditis.Rheumatoid arthritis clinical benefits from abatacept, cytokine blockers, and rituximab are all linked to modulation of memory B cell responsesCan IL-6 blockade rectify imbalance between Tregs and Th17 cells?[Methotrexate as combination partner of TNF inhibitors and tocilizumab: what is reasonable from an immunological viewpoint?].A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases.A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer.Interleukin-6 receptor inhibitor tocilizumab ameliorates periodontal inflammation in patients with rheumatoid arthritis and periodontitis as well as tumor necrosis factor inhibitors.
P2860
Q26824294-3BE10A28-E310-48A8-A927-1F47E966EE2FQ26824970-DB4713A5-FE8E-4C2E-AB9A-D5B5BA132B0BQ27002391-23DA2DDC-6F47-452B-8F2D-B2E9E4B5AFD6Q27022645-9C6907A3-294B-4F16-B1B5-729A0FAFEC4DQ28073706-8161D2FF-E663-4018-AE29-8B14DFA47A9EQ35096472-35FD409C-BD6D-43A0-B5C6-97E4AA07CE23Q35144770-72587DBA-2E91-45E7-AE7D-C9EE3DD1FC1DQ35555943-5E1F5B76-E0B7-4B0E-9830-E29565731EC1Q36173541-008DF078-6E63-4982-A49E-AC385EE04A68Q37026278-98559D5B-7A84-4470-B9A1-D74394550C9CQ37111423-E0022A62-ED80-4F7C-B82B-7B6FF75EC157Q37144548-B4BEB08C-3ACA-4482-9D2C-5C3085F5C942Q37965754-794563F3-EBC3-4D55-9A47-5428DEA70A40Q38020364-A3DA2B79-3B8E-46FA-9BF2-DA6C6F77EF77Q38036246-BFA629D9-5C25-41FC-9A2D-69CC8CD69C25Q38058508-180AD4C5-3E48-48AB-BE34-2C1E7988D14DQ38164315-2D1FE36A-DD2F-4E3C-8797-D582EA0F211EQ38197519-173736F6-9573-4D6A-A27D-5F0829996ACCQ38235570-E94CD02C-188A-4FBD-A741-4786BBCA0BCFQ38356035-2A69BE42-B828-4318-8215-EADAC198C374Q38676578-54657F54-2BDA-42A7-AE43-7CD8031707C7Q38685086-0B5C3850-CA08-45B7-A20F-AC70D539CCA9Q38826459-F09606F0-FE35-457E-A648-9929A89815CBQ38910201-1F6DBBA8-94B8-4265-A17F-BBB775BE8EB6Q40118329-54561544-C13A-41AD-B28F-D13C08DED10CQ41500669-231CEAD0-B4AB-4A54-B4D2-213B98A1C21AQ41689291-62492945-FA5D-4D1A-A4E2-FB4A347F453FQ42561719-53367878-CDB2-4498-A7AD-FC5DDE545EB5Q44212684-C07CA1F5-91B8-4CE7-B6DF-189D087231AEQ44444628-846441F9-E549-405B-9BDC-AE9B5F3E584EQ52675492-297DA443-853F-4746-AEEB-E1BC48FEF789Q53405410-1CD1DF74-8C83-4BA5-8D7C-95F580626D96Q55077160-C85A692F-1F84-466A-BBC0-956479BFF14E
P2860
In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
In vivo effects of the anti-in ...... mab on the B cell compartment.
@en
In vivo effects of the anti-in ...... mab on the B cell compartment.
@nl
type
label
In vivo effects of the anti-in ...... mab on the B cell compartment.
@en
In vivo effects of the anti-in ...... mab on the B cell compartment.
@nl
prefLabel
In vivo effects of the anti-in ...... mab on the B cell compartment.
@en
In vivo effects of the anti-in ...... mab on the B cell compartment.
@nl
P2093
P2860
P356
P1476
In vivo effects of the anti-in ...... mab on the B cell compartment.
@en
P2093
Khalid Muhammad
Mathias Schumann
Petra Roll
Stefan Kleinert
Thomas Dörner
P2860
P304
P356
10.1002/ART.30242
P577
2011-05-01T00:00:00Z